Ozempic face: what is it and how can you prevent a gaunt appearance when taking GLP-1 medication?

Short answer: ‘Ozempic face’ is the popular term for a gaunt appearance following rapid weight loss with GLP-1 medication. It is caused by the loss of facial fat and is not a recognised side effect, but rather a cosmetic effect that can be minimised by following a gradual titration schedule.

“Ozempic face” is the colloquial term for a gaunt, aged-looking face following rapid weight loss with GLP-1 medication such as Ozempic, Wegovy, Mounjaro and Saxenda. Holler cheeks, deeper lines around the mouth and a loss of youthful volume: these are recognisable signs that many users see mentioned online. But what exactly happens to your face during weight loss, why does this happen to some people but not others, and what can you do about it yourself? This blog provides an honest, medically informed answer.

What exactly is “Ozempic face”?

‘Ozempic face’ is not an official medical term or a recognised side effect of semaglutide, but a collective term that has emerged on social media. The term describes facial changes caused by significant fat loss in the face: hollow cheeks, deeper creases around the nose and mouth, and a loss of the youthful volume that makes a face appear full and relaxed.

A recent literature review describes that these changes are associated with loss of facial volume and skin thinning due to a reduction in collagen, particularly following rapid and substantial weight loss. The term itself does not originate from clinical research, but the underlying mechanisms are certainly described in the scientific literature. That distinction is important: the phenomenon is real; the label is colloquial.

What causes a sunken face following weight loss?

A sunken face occurs because the face contains a relatively large amount of subcutaneous fat, particularly in the cheeks and around the eyes. With rapid weight loss, this fat is lost, whilst the skin does not always shrink at the same rate.

Research into tissue changes following weight loss shows that skin elasticity is a crucial factor: the less elastic the skin, the greater the likelihood of visible sagging following a loss of volume. This is particularly relevant for older users, as skin elasticity and collagen production naturally decline with age. It is important to note that this is not a unique effect of GLP-1 medication, but a well-known consequence of rapid weight loss in general. Doctors also observe the same pattern following gastric bypass surgery or extreme diets.

Does this apply to all GLP-1 medicines: Ozempic, Wegovy, Mounjaro and Saxenda?

Yes, the risk depends on the amount and rate of weight loss, not on the specific molecule. Semaglutide, the active ingredient in Ozempic (semaglutide), Wegovy and Rybelsus; tirzepatide in Mounjaro (tirzepatide) and Zepbound; and liraglutide in Saxenda (liraglutide) can all cause this potential effect in the event of significant weight loss.

A network meta-analysis of body composition shows that tirzepatide results in slightly greater weight loss on average than semaglutide, which could theoretically lead to a greater effect on facial volume in the event of rapid weight loss. Liraglutide, with its more gradual action profile due to daily administration, generally shows a similar pattern, linked to the total amount of weight loss. It is therefore not a question of which medicine you use, but of how much and how quickly you lose weight.

Who is more likely to develop ‘Ozempic face’?

People who lose a lot of weight quickly – for example, more than one per cent of their body weight per week – are at the greatest risk of visible loss of facial volume. Older users naturally have less skin elasticity and collagen, meaning the skin is less able to contract as the fat disappears.

Smoking accelerates skin ageing and further reduces elasticity, which increases the risk even more. People who naturally have little facial fat are also more likely to notice volume loss sooner because they have less of a ‘buffer’. According to the Pharmacotherapeutic Compass, a gradual dose escalation is specifically intended to regulate the rate of weight loss, which indirectly also limits this risk.

How can you prevent or minimise a sunken face?

A gradual dose escalation is the first and most important measure, and this is precisely what the standard titration schedule for GLP-1 medication is already designed to achieve. A slower start gives your body and skin more time to adapt to the changing volume.

In addition, adequate protein intake whilst using GLP-1 is important, combined with strength training to maintain muscle mass, including in the jaw and neck regions. Research into muscle mass loss during GLP-1 therapy describes how targeted mitigation strategies, such as protein intake, can limit the loss of lean body mass. A study on strength training during incretin-based treatment confirms that resistance exercises have a beneficial effect on changes in body composition. Adequate hydration and basic skincare using SPF and, where appropriate, retinoids can support skin quality, although these are general recommendations with no guaranteed effect on facial volume. Always discuss any concerns about the rate of your weight loss with your treating doctor or coach.

Is a sunken face reversible?

Partially: facial volume may return to some extent once your weight stabilises, but skin elasticity recovers considerably more slowly than fat tissue. When weight stabilises, the body gradually rebuilds some fat, including in the face, which can compensate for some of the lost volume.

For people who still experience sagging skin after stabilisation, cosmetic options such as dermal fillers are available. We mention this here for information purposes only: Goodweigh does not recommend this and does not offer it as one of its own services. Such a procedure is an individual, cosmetic choice that you should discuss with a qualified specialist, separately from your GLP-1 treatment.

Ozempic and facial changes in perspective

A gaunt face is a possible aesthetic effect of rapid weight loss, not a dangerous side effect. It is not a reason to stop an effective treatment, but it is a reason to consciously monitor the pace of your weight loss. With a gradual weight loss plan, sufficient protein and coaching that monitors the pace of your weight loss, the risk can be effectively minimised. Would you like to know what realistic weight loss means for you? Read more about how much weight you can lose with Ozempic and start your initial consultation today for personalised support.